Literature DB >> 9972349

Glaucoma and quality of the life.

S Perfetti1, A Varotto, S Massagrandi, F Pagliani, L Bonomi.   

Abstract

A questionnaire was prepared and given to 332 subjects who passed through our Institute for Glaucoma with the aim of evaluating their quality of life. The diagnosis of glaucoma is associated with a diminished quality of life in a considerable percentage of the interviewed subjects. The patients are troubled most of all by the inconvenience of the treatments and the fear of visual compromission. Mitotic therapies, polytherapies and systemic therapies are the less agreeable of them. Of the therapy in itself, the most disagreeable aspects are the frequency and timetable of the medications. No quality of life differences were mentioned by surgically treated patients nor those on solely pharmacological treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9972349     DOI: 10.1111/j.1600-0420.1998.tb00887.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand Suppl        ISSN: 1395-3931


  3 in total

1.  A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.

Authors:  J García-Sánchez; J-F Rouland; D Spiegel; B Pajic; I Cunliffe; C Traverso; J Landry
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Impact of binocular integrated visual field defects on healthy related quality of life in glaucoma.

Authors:  Can Zhao; Jiao Li; Qing Cun; Yijin Tao; Wenyan Yang; Sean Tighe; Yingting Zhu; Hua Zhong
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

3.  Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.

Authors:  Shi-Ming Li; Ru Chen; Yuan Li; Zhi-Rong Yang; Qiu-Ju Deng; Zheng Zhong; Moh-Lim Ong; Si-Yan Zhan
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.